The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in patients with breast cancer: A retrospective analysis.
N. Ngamphaiboon
No relevant relationships to disclose
P. P. Advani
No relevant relationships to disclose
T. L. O'Connor
No relevant relationships to disclose
F. O. Ademuyiwa
No relevant relationships to disclose
E. G. Levine
No relevant relationships to disclose
G. Riebandt
No relevant relationships to disclose
E. B. Kossoff
No relevant relationships to disclose